<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/CFAA70A9-58F6-4917-9260-A4338890F14F"><gtr:id>CFAA70A9-58F6-4917-9260-A4338890F14F</gtr:id><gtr:firstName>Guy</gtr:firstName><gtr:otherNames>Allen</gtr:otherNames><gtr:surname>Rutter</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/764BFB86-B856-4EF9-A70A-8C96278A0848"><gtr:id>764BFB86-B856-4EF9-A70A-8C96278A0848</gtr:id><gtr:firstName>Jorge</gtr:firstName><gtr:surname>Ferrer</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FL02036X%2F1"><gtr:id>DA49F355-668C-48A6-95AB-191D3ACD6767</gtr:id><gtr:title>Targeting etiologic molecular mechanisms to treat human diabetes</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L02036X/1</gtr:grantReference><gtr:abstractText>One of the major goals of modern medicine is to develop more efficient personalized therapies for diseases that impose a heavy burden on our society, including debilitating chronic diseases such as diabetes mellitus. The drugs that are currently used to treat diabetes do not aim to correct the molecular causes of the disease but simply aim to lower blood sugar, and therefore do not prevent disease progression. The most common form of this disease is known as Type 2 diabetes. Recent genetic studies have pinpointed to candidate genetic factors that predispose to this form of diabetes. This promises to facilitate the development of treatments that target specific genes that are truly involved in the disease mechanisms. Such treatments can theoretically be more efficient for individuals in whom diabetes is shown to be caused by those particular mechanisms. In this project we have set out to discover novel therapies that target the molecular mechanism in patients who develop diabetes due to mutations in a gene named HNF1A. This defect is the most common form of diabetes in which the genetic derangement is unequivocally established, although it is rare compared to the overall frequency of Type 2 diabetes. Nonetheless, there is evidence indicating that some genetic factors associated to HNF1A might also affect the risk to develop more common classic forms of Type 2 diabetes. Because the genetic defect in HNF1A diabetes is clear, it provides an ideal test bed to develop therapies that target genetic factors in diabetes. We will use a combination of chemical and genomic approaches to identify candidate compounds to treat HNF1A diabetes, and also to unravel the mechanisms that mediate their beneficial effects. We will also create new models of HNF1A-deficient diabetes for testing and developing new drugs. This programme is therefore designed to deliver novel candidate therapies for people with mutations in the HNF1A gene, and theoretically for a subset of individuals with Type 2 diabetes that have genetic risk factors associated with this same gene. The therapies that we propose to develop have the potential to be rapidly translated into the clinic. These drugs can impact the underlying causes and thereby modify the progression of disease.</gtr:abstractText><gtr:technicalSummary>One of the major goals of modern medicine is to develop more efficient personalized therapies to treat chronic diseases that impose a heavy burden on our society. Recent progress in our understanding of the genetic predisposition of Type 2 diabetes promises to facilitate personalized therapies that target the molecular mechanisms that underlie this disease. We have set out to discover novel therapies that target the molecular mechanism in patients who develop early-onset diabetes to heterozygous mutations in the gene encoding the transcription factor HNF1A. This genetic defect represents the most common known form of Mendelian diabetes. Although it is rare compared to classic late-onset Type 2 diabetes, sequence variants near HNF1A predispose to late-onset disease, suggesting that different variants in the same locus might lead to different forms of diabetes. HNF1A-deficient diabetes is of interest to us because it has a clearly recognizable molecular defect. In the current proposal we plan to develop novel therapies that target this molecular defect. We will use an integrative chemical and genomic approach that is designed to uncover the molecular mechanisms that mediate the beneficial effects of novel therapies. We will also create new genetic models of HNF1A-deficient diabetes for in vivo drug testing and development. In conclusion, this programme is expected to deliver candidate targeted therapeutics for patients with highly penetrant mutations in HNF1A, and possibly for individuals that harbor Type 2 diabetes risk variants in the HNF1A locus. Such therapies have the potential for rapid translation into the clinic, and unlike current drugs that simply modify glycemia, they can impact the underlying pathogenic defects and thereby modify the progression of disease.</gtr:technicalSummary><gtr:potentialImpactText>The primary beneficiaries of the research proposed here should be the general public, the UK Pharmaceutical industry, and the Scientific community. 

1. UK healthcare. Type 2 diabetes affects ~3m UK subjects and ~30m Europeans. These values are predicted to grow further in an &amp;quot;epidemic&amp;quot; driven by increasingly sedentary lifestyles and obesity. The disease is a major cause of stroke, blindness, amputations painful neuropathy, renal failure, cardiovascular disease and is now also associated to increased risk of cancer. The high prevalence of diabetes was recently predicted to contribute to a lowered overall life expectancy in the UK for the first time in 200 years. The direct economic costs account for 7-13 % of health care costs in most developed societies (IDF Diabetes Atlas, 2003) and are further aggravated by increased absenteeism and decreased individual productivity. 
One of the major goals of modern medicine is to develop personalized medicines. It is widely accepted that Type 2 diabetes is a heterogeneous disorder, and therefore different patients are expected to respond differently to diverse therapies. A small proportion of patients diagnosed with Type 2 diabetes have severe defects in the HNF1A gene, whereas many others have sequence variants near this gene, potentially regulating HNF1A, which increase the risk for developing Type 2 diabetes. This project seeks to identify therapies that specifically ameliorate diabetes in those individuals in which HNF1A plays a role in the development of the disease. Furthermore, because the treatment does not simply ameliorate blood sugar, but actual targets the molecular cause, it has the potential to block the progression of the disease. This could have significant impact on the requirement of further medications such as insulin, and most importantly may impact chronic complications that are a major burden for western healthcare systems. 

2. The UK Pharmaceutical Industry. The global market for anti-diabetes drugs is estimated to be worth ~$30 billion. Following its joint Workshop with the Association of British Pharmaceutical Industries (ABPI) in March 2011, the MRC concluded that pancreatic beta cell biology should become a Strategic Priority, alongside Stratified Medicine. The present application addresses both of these areas. New drug targets and leads are desperately needed for the Pharmaceutical industry to produce novel approaches to diabetes treatment. By addressing a target that is unequivocally important for human beta cells, the proposed study will enhance feeds of new Intellectual Property to this sector. 
Numerous pharmaceutical companies have a specific interest in the development of novel types of therapies diabetes. The PIs are members of two trans-European diabetes academic and industrial partnerships named &amp;quot;DIRECT&amp;quot; http://www.direct-diabetes.org/ (JF) and &amp;quot;IMIDIA&amp;quot; (http://www.imidia.org/) (GR). The PIs therefore have excellent continued access to UK and Europe-based companies and plan to approach them to exploit the findings for the development of new diabetes therapies. 

3. The scientific community. This programme aims to demonstrate the utility of a therapeutic strategy that has potential ramifications for the treatment of human haploinsufficient conditions beyond diabetes. It will also generate knowledge on central regulatory mechanisms in pancreatic beta cells, and provide a broad range of chemical and genetic research tools that should accelerate research in the islet research field. Collaborative interactions with clinical diabetes investigators will help advance clinical science in UK. Finally, the programme will have a significant training component. Each of the research fellows directly involved in the project will enhance their professional skills with training in basic biomedical research and thus their develop their skill set for application in both the academic and commercial sectors.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-10-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1860023</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Participated in a CREST activity.</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A4A91A96-8741-4318-ACDD-26ED3C35533B</gtr:id><gtr:impact>Mentoring students.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.crestawards.org/</gtr:url><gtr:year>2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mentoring of High School Students</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F1E19E84-DA01-4419-B257-5CC9A11F662D</gtr:id><gtr:impact>Four high school students have had 1 - 2 week work placements and mentoring.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Neonatal Diabetes Day - Exeter University</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E854F3B4-5E65-459F-94DD-CB69DB268984</gtr:id><gtr:impact>Presented a talk and took part in a debate.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:url>http://www.exeter.ac.uk/research/feature/diabetes/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Engagement Lecture - The Academy of Medical Sciences, supper club, Norwich, UK.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>18E66AEA-C9EC-4274-A0A0-F7CF4D074275</gtr:id><gtr:impact>Presentation to the The Academy of Medical Sciences Supper Club, followed by debate.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://acmedsci.ac.uk/grants-and-schemes/events/regional-events</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>- Annotations of human pancreatic islet long non-coding RNAs
- Annotations of regulatory elements in human embryonic pancreas
- Annotations of regulatory elements in human pancreatic islets</gtr:description><gtr:id>8A70086D-BE02-4598-9E9A-F468BCD88FAC</gtr:id><gtr:impact>- Annotations of human pancreatic islet long non-coding RNAs
- Annotations of regulatory elements in human embryonic pancreas
- Annotations of regulatory elements in human pancreatic islets</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Generation of the following epigenomic annotations</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Conditional mouse allele for cell-specific inactivation of the Hnf1a gene in pancreas, liver, gut, beta cells, glucagon cells (Hnf1a LoxP/LoxP + cell-specific Cre)
Knock-in mouse model for analysis of human Hnf1a disease-causing mutations
Deletion mouse model to study regulatory mutations causing neonatal diabetes
Ins1Cre - Cre recombinase is expressed in insulin-producing beta cells of the pancreas.
Ins1CreER - Cre-ERT2 is expressed in insulin-producing beta cells of the pancreas. This model is useful for applications requiring tamoxifen-induced deletion of floxed sequences in beta cells.</gtr:description><gtr:id>5CA04C57-FBD3-4CA3-9F0D-8BBD5A2646B7</gtr:id><gtr:impact>This model is useful for applications requiring tamoxifen-induced deletion of floxed sequences in beta cells.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Generation of the following mouse models</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8474FD87-62A3-4343-9AA7-00FF2785E6A2"><gtr:id>8474FD87-62A3-4343-9AA7-00FF2785E6A2</gtr:id><gtr:title>TEAD and YAP regulate the enhancer network of human embryonic pancreatic progenitors.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f08ad252f7e497f5caf1732a19a0a328"><gtr:id>f08ad252f7e497f5caf1732a19a0a328</gtr:id><gtr:otherNames>Cebola I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/02A2EF69-3873-4ADB-9732-D7018A4641C4"><gtr:id>02A2EF69-3873-4ADB-9732-D7018A4641C4</gtr:id><gtr:title>Selective disruption of Tcf7l2 in the pancreatic ? cell impairs secretory function and lowers ? cell mass.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f40e1e64032af61ab455c03a6977b343"><gtr:id>f40e1e64032af61ab455c03a6977b343</gtr:id><gtr:otherNames>Mitchell RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B190C849-CED1-4520-B290-51C556E84034"><gtr:id>B190C849-CED1-4520-B290-51C556E84034</gtr:id><gtr:title>Cell cycle-dependent differentiation dynamics balances growth and endocrine differentiation in the pancreas.</gtr:title><gtr:parentPublicationTitle>PLoS biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b67055dbffe4403629783cde7426e61c"><gtr:id>b67055dbffe4403629783cde7426e61c</gtr:id><gtr:otherNames>Kim YH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1544-9173</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E01A9D59-1032-422D-B9F2-E7E569C5D4C5"><gtr:id>E01A9D59-1032-422D-B9F2-E7E569C5D4C5</gtr:id><gtr:title>Beta Cell Hubs Dictate Pancreatic Islet Responses to&amp;nbsp;Glucose.</gtr:title><gtr:parentPublicationTitle>Cell metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7c7cf81304cde387c0ee09db1d798661"><gtr:id>7c7cf81304cde387c0ee09db1d798661</gtr:id><gtr:otherNames>Johnston NR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1550-4131</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7E4B976F-9B2B-4BD6-B1C0-1386B085E5E6"><gtr:id>7E4B976F-9B2B-4BD6-B1C0-1386B085E5E6</gtr:id><gtr:title>Can Insulin Production Suppress ? Cell Growth?</gtr:title><gtr:parentPublicationTitle>Cell metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/971d82d0d9b772c749da022bd2b93100"><gtr:id>971d82d0d9b772c749da022bd2b93100</gtr:id><gtr:otherNames>De Vas M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1550-4131</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EF6895EE-76FC-46FB-B3B8-380A4329E0E8"><gtr:id>EF6895EE-76FC-46FB-B3B8-380A4329E0E8</gtr:id><gtr:title>Human Pancreatic ? Cell lncRNAs Control Cell-Specific Regulatory Networks.</gtr:title><gtr:parentPublicationTitle>Cell metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5c6050898808bf947974f63e479b92ce"><gtr:id>5c6050898808bf947974f63e479b92ce</gtr:id><gtr:otherNames>Akerman I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1550-4131</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E9E1DEDB-54BC-460A-A966-4FF19B0BF92A"><gtr:id>E9E1DEDB-54BC-460A-A966-4FF19B0BF92A</gtr:id><gtr:title>Transcriptional enhancers: functional insights and role in human disease.</gtr:title><gtr:parentPublicationTitle>Current opinion in genetics &amp; development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fa9406436655c7de60e64a026865aa9d"><gtr:id>fa9406436655c7de60e64a026865aa9d</gtr:id><gtr:otherNames>Miguel-Escalada I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0959-437X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/87FDE59A-0FD4-4826-95F3-B4F6CA923801"><gtr:id>87FDE59A-0FD4-4826-95F3-B4F6CA923801</gtr:id><gtr:title>Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/697f9452313f015b132e006fdfc1e038"><gtr:id>697f9452313f015b132e006fdfc1e038</gtr:id><gtr:otherNames>Marquard J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/25EC71FC-0832-4772-A944-4590C9EED2B6"><gtr:id>25EC71FC-0832-4772-A944-4590C9EED2B6</gtr:id><gtr:title>Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/372a17a19f0aa4ad420ec523b27f31e2"><gtr:id>372a17a19f0aa4ad420ec523b27f31e2</gtr:id><gtr:otherNames>Gaulton KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E1AEB2BF-EAA9-4495-BB1B-6B5F29B9A30A"><gtr:id>E1AEB2BF-EAA9-4495-BB1B-6B5F29B9A30A</gtr:id><gtr:title>The FOXP1, FOXP2 and FOXP4 transcription factors are required for islet alpha cell proliferation and function in mice.</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2ebe5ddeb693b130318d26cb5eb87207"><gtr:id>2ebe5ddeb693b130318d26cb5eb87207</gtr:id><gtr:otherNames>Spaeth JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5D3FF043-2AFF-4E8A-A32B-C39F23D40798"><gtr:id>5D3FF043-2AFF-4E8A-A32B-C39F23D40798</gtr:id><gtr:title>Weaning gives ? cells license to regenerate.</gtr:title><gtr:parentPublicationTitle>Developmental cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/661a6fbc4305b06912a4aff7def817bc"><gtr:id>661a6fbc4305b06912a4aff7def817bc</gtr:id><gtr:otherNames>Rovira M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1534-5807</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0563E1BD-F743-4509-9DD2-414846D2FCB2"><gtr:id>0563E1BD-F743-4509-9DD2-414846D2FCB2</gtr:id><gtr:title>Ins1(Cre) knock-in mice for beta cell-specific gene recombination.</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/84c7552094599d2e5faede2d37d5a309"><gtr:id>84c7552094599d2e5faede2d37d5a309</gtr:id><gtr:otherNames>Thorens B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/65C3A110-23E2-4CB2-A5FE-17A095C678F8"><gtr:id>65C3A110-23E2-4CB2-A5FE-17A095C678F8</gtr:id><gtr:title>TEAD and YAP regulate the enhancer network of human embryonic pancreatic progenitors.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f08ad252f7e497f5caf1732a19a0a328"><gtr:id>f08ad252f7e497f5caf1732a19a0a328</gtr:id><gtr:otherNames>Cebola I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L02036X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>